WallStreetZenWallStreetZen

NASDAQ: BIOA
Bioage Labs Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIOA

Based on 1 analyst offering 12 month price targets for Bioage Labs Inc

Min Forecast
$15.00+76.68%
Avg Forecast
$15.00+76.68%
Max Forecast
$15.00+76.68%

Should I buy or sell BIOA stock?

Based on 1 analyst offering ratings for Bioage Labs Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BIOA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BIOA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their BIOA stock forecasts and price targets.

BIOA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-29

1 of 1

Forecast return on equity

Is BIOA forecast to generate an efficient return?

Company
N/A
Industry
285.61%
Market
230.63%

Forecast return on assets

Is BIOA forecast to generate an efficient return on assets?

Company
N/A
Industry
157.02%

BIOA earnings per share forecast

What is BIOA's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$2.35-117.23%
Avg 2 year Forecast
-$2.97-121.79%
Avg 3 year Forecast
-$3.10-122.78%

BIOA revenue forecast

What is BIOA's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$7.2M+21.6%
Avg 2 year Forecast
$2.9M-50.35%
Avg 3 year Forecast
$2.3M-61.21%
BIOA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIOA revenue growth forecast

How is BIOA forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
-34.11%
Industry
132.21%
Market
25.71%
BIOA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIOA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIOA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
BIOA$8.49$15.00+76.68%Strong Buy
LFCR$7.72N/AN/A
ACB$4.48N/AN/A
TKNO$4.42N/AN/A
CGC$1.11N/AN/A
View Top Pharmaceutical Stocks

Bioage Labs Stock Forecast FAQ

Is Bioage Labs Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BIOA) stock is to Strong Buy BIOA stock.

Out of 1 analyst, 1 (100%) are recommending BIOA as a Strong Buy, 0 (0%) are recommending BIOA as a Buy, 0 (0%) are recommending BIOA as a Hold, 0 (0%) are recommending BIOA as a Sell, and 0 (0%) are recommending BIOA as a Strong Sell.

If you're new to stock investing, here's how to buy Bioage Labs stock.

What is BIOA's earnings growth forecast for 2025-2027?

(NASDAQ: BIOA) Bioage Labs's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 364.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.09%.

Bioage Labs's earnings in 2025 is -$75,791,000.On average, 7 Wall Street analysts forecast BIOA's earnings for 2025 to be -$84,101,575, with the lowest BIOA earnings forecast at -$98,386,222, and the highest BIOA earnings forecast at -$77,554,445. On average, 7 Wall Street analysts forecast BIOA's earnings for 2026 to be -$106,328,112, with the lowest BIOA earnings forecast at -$112,792,775, and the highest BIOA earnings forecast at -$99,766,640.

In 2027, BIOA is forecast to generate -$111,179,299 in earnings, with the lowest earnings forecast at -$117,009,328 and the highest earnings forecast at -$106,543,242.

What is BIOA's revenue growth forecast for 2025-2027?

(NASDAQ: BIOA) Bioage Labs's forecast annual revenue growth rate of -34.11% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 132.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.71%.

Bioage Labs's revenue in 2025 is $5,917,000.On average, 7 Wall Street analysts forecast BIOA's revenue for 2025 to be $257,976,991, with the lowest BIOA revenue forecast at $207,923,360, and the highest BIOA revenue forecast at $301,827,701. On average, 7 Wall Street analysts forecast BIOA's revenue for 2026 to be $105,342,099, with the lowest BIOA revenue forecast at $0, and the highest BIOA revenue forecast at $316,241,426.

In 2027, BIOA is forecast to generate $82,287,310 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $188,238,944.

What is BIOA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BIOA) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 157.02%.

What is BIOA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BIOA price target, the average BIOA price target is $15.00, with the highest BIOA stock price forecast at $15.00 and the lowest BIOA stock price forecast at $15.00.

The Wall Street analyst predicted that Bioage Labs's share price could reach $15.00 by Oct 29, 2026. The average Bioage Labs stock price prediction forecasts a potential upside of 76.68% from the current BIOA share price of $8.49.

What is BIOA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BIOA) Bioage Labs's current Earnings Per Share (EPS) is $13.61. On average, analysts forecast that BIOA's EPS will be -$2.35 for 2025, with the lowest EPS forecast at -$2.74, and the highest EPS forecast at -$2.16. On average, analysts forecast that BIOA's EPS will be -$2.97 for 2026, with the lowest EPS forecast at -$3.15, and the highest EPS forecast at -$2.78. In 2027, BIOA's EPS is forecast to hit -$3.10 (min: -$3.26, max: -$2.97).

What is BIOA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BIOA) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.